Breast Cancer Treatment Pioneer George W. Sledge, Jr, MD, Joins CME Enterprise Advisory Board.Pioneer in the Development of Novel Therapies for Breast Cancer to Provide Guidance on Curriculum Development CARMEL, Ind. -- CME CME See: Chicago Mercantile Exchange CME See Chicago Mercantile Exchange (CME). Enterprise today announced the addition of noted oncologist George W. Sledge, Jr, MD, to its CME Advisory Board. Dr. Sledge currently serves as Ballve-Lantero Professor of Oncology at the Indiana University School of Medicine The Indiana University School of Medicine is the medical school of Indiana University, part of the Indiana University Purdue University at Indianapolis (IUPUI) campus located in Indianapolis, Indiana. Established in 1903, the school had an initial class of 25 students. . He is recognized as one of the first cancer researchers investigating angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. therapies to prevent the development of new blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. in human cancers. "The addition of Dr. Sledge to our CME advisory board will greatly enhance our ability to assess the educational needs of the physicians we serve, particularly in the area of newly developing treatments for breast cancer," said Winston Satterlee, MD, Chairman of the medical advisory board at CME Enterprise. "His work has resulted in improved therapies for women with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer that have saved countless lives." Dr. Sledge led the first-ever trial of an anti-VEGF monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing for the treatment of metastatic breast cancer. His involvement with the design and implementation of these trials led to the development of adjuvant therapies that increase the survival rate among women with this form of the disease. "Beyond the mandated continuing education requirements physicians must fulfill, we also have a moral duty to learn as much as possible about emerging therapies in order to best serve our patients," said Dr. Sledge. "I am proud to be a part of meeting the educational needs of physicians striving to remain aware of new medical solutions as soon as they are developed in order to positively affect patient outcomes as quickly as possible." In addition to his duties at the Indiana University School of Medicine, Dr. Sledge serves on the board of directors of the American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. . He is also a member of the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational and the Hoosier Oncology Group, as well as many other professional societies. He serves on the editorial boards of The Breast Journal, Clinical Cancer Research, and Clinical Breast Cancer. About CME Enterprise CME Enterprise, an ACCME-accredited provider with Exemplary Status in Mission, Needs Assessment, and Effective Measurement of Activities, develops extensive needs assessments, executes needs-based curricula, and impacts practitioner knowledge and patient outcomes through local, national, and international CME interventions. Its core expertise is linking educational needs, knowledge gaps, and desired results through credited education with measurable outcomes. For more information about CME Enterprise, visit their Web site at www.cmeenterprise.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion